Peripheral Artery Occlusive Disease (PAOD) - Pipeline Review, H2 2015

Date: September 23, 2015
Pages: 236
Price:
US$ 2,000.00 US$ 1,600.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: P052AE6E3DEEN
Leaflet:

Download PDF Leaflet

Peripheral Artery Occlusive Disease (PAOD) - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, ‘Peripheral Artery Occlusive Disease (PAOD) - Pipeline Review, H2 2015’, provides an overview of the Peripheral Artery Occlusive Disease (PAOD)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Peripheral Artery Occlusive Disease (PAOD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Artery Occlusive Disease (PAOD) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Peripheral Artery Occlusive Disease (PAOD)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Peripheral Artery Occlusive Disease (PAOD) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Peripheral Artery Occlusive Disease (PAOD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Peripheral Artery Occlusive Disease (PAOD) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Peripheral Artery Occlusive Disease (PAOD)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Peripheral Artery Occlusive Disease (PAOD) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Peripheral Artery Occlusive Disease (PAOD) Overview
Therapeutics Development
Pipeline Products for Peripheral Artery Occlusive Disease (PAOD) - Overview
Pipeline Products for Peripheral Artery Occlusive Disease (PAOD) - Comparative Analysis
Peripheral Artery Occlusive Disease (PAOD) - Therapeutics under Development by Companies
Peripheral Artery Occlusive Disease (PAOD) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Peripheral Artery Occlusive Disease (PAOD) - Products under Development by Companies
Peripheral Artery Occlusive Disease (PAOD) - Companies Involved in Therapeutics Development
Alvogen Korea
AnGes MG, Inc.
Annexin Pharmaceuticals AB
Apceth GmbH & Co. KG
AstraZeneca Plc
Athersys, Inc.
Bayer AG
Betagenon AB
Cardiolynx AG
CardioVascular BioTherapeutics, Inc.
Celgene Corporation
Cytokinetics, Inc.
Diffusion Pharmaceuticals LLC
DNAVEC Corporation
Eli Lilly and Company
Grifols, S.A.
Juventas Therapeutics, Inc.
Kowa Company, Ltd.
Lacer, S.A.
LTT Bio-Pharma Co., Ltd.
MedImmune, LLC
miRagen Therapeutics, Inc.
Multi Gene Vascular Systems Ltd
Nuo Therapeutics, Inc.
Pluristem Therapeutics Inc.
Proteon Therapeutics, Inc.
Recardio GmbH
RegenoCELL Therapeutics, Inc.
Resverlogix Corp.
Sagene Pharmaceuticals, Inc.
Stemedica Cell Technologies, Inc.
Symic Biomedical, Inc.
Theravasc, Inc.
vasopharm GmbH
ViroMed Co., Ltd.
Yuyu Pharma, Inc.
Peripheral Artery Occlusive Disease (PAOD) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(cilostazol + organic nitrate) ER - Drug Profile
AEM-28 - Drug Profile
ALD-301 - Drug Profile
Alecmestencel-T - Drug Profile
Annexin A-5 - Drug Profile
AP-01 - Drug Profile
apabetalone - Drug Profile
beperminogene perplasmid - Drug Profile
CVBT-141C - Drug Profile
DVC1-0101 - Drug Profile
ELS-140 - Drug Profile
evacetrapib - Drug Profile
Gene Therapy for Critical Limb Ischemia and Peripheral Arterial Disease - Drug Profile
Human Plasmin - Drug Profile
JVS-100 - Drug Profile
K-134 - Drug Profile
LA-419 - Drug Profile
LT-0101 - Drug Profile
MEDI-6012 - Drug Profile
Mesenchymal Stem Cells - Drug Profile
MGN-6114 - Drug Profile
MultiGeneAngio - Drug Profile
MultiGeneGraft - Drug Profile
MultiStem - Drug Profile
O-304 - Drug Profile
PDA-002 - Drug Profile
PLX-PAD - Drug Profile
REC-03 - Drug Profile
rivaroxaban - Drug Profile
sarpogrelate SR - Drug Profile
SBCV-030 - Drug Profile
selegiline + Antiplatelet Drugs - Drug Profile
sodium nitrite SR - Drug Profile
Stem Cell Therapy for Cardiovascular Diseases - Drug Profile
ticagrelor - Drug Profile
tirasemtiv - Drug Profile
transcrocetinate sodium - Drug Profile
TXA-127 - Drug Profile
VAS-2870 - Drug Profile
VM-202 - Drug Profile
vonapanitase - Drug Profile
YY-984 - Drug Profile
Peripheral Artery Occlusive Disease (PAOD) - Recent Pipeline Updates
Peripheral Artery Occlusive Disease (PAOD) - Dormant Projects
Peripheral Artery Occlusive Disease (PAOD) - Discontinued Products
Peripheral Artery Occlusive Disease (PAOD) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Peripheral Artery Occlusive Disease (PAOD), H2 2015
Number of Products under Development for Peripheral Artery Occlusive Disease (PAOD) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd..1)
Number of Products under Development by Companies, H2 2015 (Contd..2)
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Alvogen Korea, H2 2015
Peripheral Artery Occlusive Disease (PAOD) - Pipeline by AnGes MG, Inc., H2 2015
Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Annexin Pharmaceuticals AB, H2 2015
Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Apceth GmbH & Co. KG, H2 2015
Peripheral Artery Occlusive Disease (PAOD) - Pipeline by AstraZeneca Plc, H2 2015
Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Athersys, Inc., H2 2015
Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Bayer AG, H2 2015
Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Betagenon AB, H2 2015
Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Cardiolynx AG, H2 2015
Peripheral Artery Occlusive Disease (PAOD) - Pipeline by CardioVascular BioTherapeutics, Inc., H2 2015
Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Celgene Corporation, H2 2015
Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Cytokinetics, Inc., H2 2015
Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Diffusion Pharmaceuticals LLC, H2 2015
Peripheral Artery Occlusive Disease (PAOD) - Pipeline by DNAVEC Corporation, H2 2015
Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Eli Lilly and Company, H2 2015
Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Grifols, S.A., H2 2015
Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Juventas Therapeutics, Inc., H2 2015
Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Kowa Company, Ltd., H2 2015
Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Lacer, S.A., H2 2015
Peripheral Artery Occlusive Disease (PAOD) - Pipeline by LTT Bio-Pharma Co., Ltd., H2 2015
Peripheral Artery Occlusive Disease (PAOD) - Pipeline by MedImmune, LLC, H2 2015
Peripheral Artery Occlusive Disease (PAOD) - Pipeline by miRagen Therapeutics, Inc., H2 2015
Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Multi Gene Vascular Systems Ltd, H2 2015
Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Nuo Therapeutics, Inc., H2 2015
Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Pluristem Therapeutics Inc., H2 2015
Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Proteon Therapeutics, Inc., H2 2015
Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Recardio GmbH, H2 2015
Peripheral Artery Occlusive Disease (PAOD) - Pipeline by RegenoCELL Therapeutics, Inc., H2 2015
Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Resverlogix Corp., H2 2015
Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Sagene Pharmaceuticals, Inc., H2 2015
Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Stemedica Cell Technologies, Inc., H2 2015
Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Symic Biomedical, Inc., H2 2015
Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Theravasc, Inc., H2 2015
Peripheral Artery Occlusive Disease (PAOD) - Pipeline by vasopharm GmbH, H2 2015
Peripheral Artery Occlusive Disease (PAOD) - Pipeline by ViroMed Co., Ltd., H2 2015
Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Yuyu Pharma, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Peripheral Artery Occlusive Disease (PAOD) Therapeutics - Recent Pipeline Updates, H2 2015
Peripheral Artery Occlusive Disease (PAOD) - Dormant Projects, H2 2015
Peripheral Artery Occlusive Disease (PAOD) - Dormant Projects (Contd..1), H2 2015
Peripheral Artery Occlusive Disease (PAOD) - Dormant Projects (Contd..2), H2 2015
Peripheral Artery Occlusive Disease (PAOD) - Dormant Projects (Contd..3), H2 2015
Peripheral Artery Occlusive Disease (PAOD) - Dormant Projects (Contd..4), H2 2015
Peripheral Artery Occlusive Disease (PAOD) - Discontinued Products, H2 2015
Peripheral Artery Occlusive Disease (PAOD) - Discontinued Products (Contd..1), H2 2015

LIST OF FIGURES

Number of Products under Development for Peripheral Artery Occlusive Disease (PAOD), H2 2015
Number of Products under Development for Peripheral Artery Occlusive Disease (PAOD) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

COMPANIES MENTIONED

Alvogen Korea
AnGes MG, Inc.
Annexin Pharmaceuticals AB
Apceth GmbH & Co. KG
AstraZeneca Plc
Athersys, Inc.
Bayer AG
Betagenon AB
Cardiolynx AG
CardioVascular BioTherapeutics, Inc.
Celgene Corporation
Cytokinetics, Inc.
Diffusion Pharmaceuticals LLC
DNAVEC Corporation
Eli Lilly and Company
Grifols, S.A.
Juventas Therapeutics, Inc.
Kowa Company, Ltd.
Lacer, S.A.
LTT Bio-Pharma Co., Ltd.
MedImmune, LLC
miRagen Therapeutics, Inc.
Multi Gene Vascular Systems Ltd
Nuo Therapeutics, Inc.
Pluristem Therapeutics Inc.
Proteon Therapeutics, Inc.
Recardio GmbH
RegenoCELL Therapeutics, Inc.
Resverlogix Corp.
Sagene Pharmaceuticals, Inc.
Stemedica Cell Technologies, Inc.
Symic Biomedical, Inc.
Theravasc, Inc.
vasopharm GmbH
ViroMed Co., Ltd.
Skip to top


Diabetic Neuropathy - Pipeline Review, H2 2016 US$ 2,000.00 Nov, 2016 · 117 pages

Ask Your Question

Peripheral Artery Occlusive Disease (PAOD) - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: